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Abstract 
 
(C^N) and (C^N^C) cyclometalated Au(III) represent a highly promising class of potential anticancer 
agents. We report here the synthesis of seven new cyclometalated Au(III) complexes with five of them 
bearing an acridine moiety attached via (N^O) or (N^N) chelates, acyclic amino carbenes (AAC) and N-
heterocyclic carbenes (NHC). The antiproliferative properties of the different complexes were evaluated in 
vitro on a panel of cancer cells including leukaemia, lung and breast cancer cells. We observed a trend 
between the cytotoxicity and the intracellular gold uptake of some representative compounds of the series. 
Some of the acridine-decorated complexes were demonstrated to interact with ds-DNA using FRET-
melting techniques.  
 
Introduction 
The worldwide approval of cisplatin for the treatment of several cancers in the late 1970s was the starting 
point of the modern use of metal complexes in medicine.1 However, the poor selectivity of cisplatin for 
cancer cells over healthy fast growing cells induces severe side effects which limits the dose of 
chemotherapy given to patients,2 and both intrinsic and acquired resistance reduces the effectiveness of 
platinum-based drugs.3 For these reasons there has been an increasing interest in the development of 
alternatives to platinum-based compounds for therapeutic purposes, including iron, copper, ruthenium, 
titanium and goldcomplexes.4-8 In particular, cyclometalated gold(III) complexes have been attracting 
significant interest.9,10 Both bidentate, (C^N) or tridentate, (C^N^C), (C^N^N) or (N^C^N) cyclometalated 
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ligands have been used to stabilize the gold(III) centre, enabling the study of fundamental organometallic 
reactions, the characterization of catalytic intermediates, and the development of photoluminescent 
materials and of anticancer drug candidates.11-13 
 Henderson and coworkers introduced a series of neutral cyclometalated (C^N)Au(N^N) chelate 
complexes containing phenylenediamine and ethylenediamine moieties, with the nitrogen atoms bearing 
electron-withdrawing moieties. The derivatives were tested for their in vitro cytotoxicity against mouse 
leukaemia cells (P388) and some showed very promising results in comparison to cisplatin. Several 
different (C^N) cyclometalated ligands were used, including the 6-membered ring based on 2-benzyl 
pyridine, and more rigid 2-phenyl pyridine complexes, combined with (N^O) and (O^O) chelate ligands 
(Figure 1, structures A - C).14,15 Other examples include (C^N)-(N^N) derivatives reported by Zhang et 
al., such as the stable and water soluble cationic gold(III) complex, [Au(butyl-C^N)biguanidine]Cl, 
(Figure 1, structure D) which combined the lipophilic, cyclometalated (C^N) ligand and the hydrophilic, 
H-bonding NH2 groups of the biguanidine ligand. The complex showed high cytotoxicity towards cancer 
cell lines, with IC50 values in the low micromolar range, as well as a high selectivity profile towards 
cancer cells over healthy CCD-19-Lu cells.16 
 
 
 
Figure 1. Examples of previously reported cyclometallated gold(III) complexes tested for anticancer 
purposes.14-18 
 
We have recently described the synthesis and anticancer activity of novel cyclometalated (C^Npz^C) 
goldIII complexes with acyclic amino carbene (AAC) ligands enabling the introduction of amines and 
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amino ester derivatives in the [(C^Npz^C)Au(carbene)]+ scaffold (Figure 1, structures E and F). The 
antiproliferative screening of these complexes identified them as promising potential chemotherapeutic 
agents.17,18 Gold(III) N-heterocyclic carbene (NHC) complexes appear to be more stable towards reducing 
agents like GSH and are highly cytotoxic towards cancer cell lines; for example, complex F showed IC50 
values in the micromolar and sub-micromolar range against a panel of cancer cell lines.18 In spite of the 
structural and electronic similarity between gold(III) and platinum(II) compounds, the two metals appear 
to have very different intracellular targets and the binding of gold(III) complexes to DNA is often weak 
and reversible.19 However, it is possible to enhance interactions of gold(III) complexes with double-
stranded DNA by optimizing the choice of the ligand toward that application.20 
Acridines are known to bind to DNA by intercalation; by the direct insertion of the three planar 
aromatic rings in between the base pairs of DNA which causes unwinding of the double helix.21,22 For 
example, Janočková et al. synthesized a series of acridine analogues, (figure 2) and demonstrated their 
ability to inhibit cancer cell growth in acute promyelocytic leukaemia cells (HL60) with IC50 values in the 
low micromolar range. DNA binding studies towards calf thymus DNA showed a strong interaction 
through DNA intercalation resulting in the inhibition of certain enzymes such as topoisomerase 1 and 2.21 
Howell et al. also studied the DNA binding and in-vitro cytotoxicity of 9-aminoacridinecarboxamides 
(Figure 2), towards various types of tertiary DNA structures. The derivatives were shown to target G-
quadruplex structures with some selectivity.23 There are also examples of acridine motifs being used to 
enhance the cytotoxicity of metal-based chemotherapeutic agents with platinum, iron, iridium or rhodium 
metal centres. In all cases, the presence of the acridine increased the interactions of the complexes with 
DNA.24,25 
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Figure 2. Examples of acridine derivatives and acridine-based metal complexes G – L tested for 
anticancer applications, and the structures of starting materials 1 – 3 showing the numbering scheme used 
for the NMR assignments. 
 
Although examples of cytotoxic gold(I)-acridine hybrids have been reported with thiourea and NHC 
ligands (Figure 2, structures K and L),26 to the best of our knowledge, no gold(III)-acridine conjugates 
have been described so far. In the present article, we report on the synthesis and anticancer activity of 
cyclometalated gold(III) complexes decorated with acridinyl substituents, based on the starting materials 1 
– 3 (Figure 2). We focus on (i) neutral (C^N)-(N^O) and (C^N)-(N^N) derivatives, and (ii) (C^Npz^C) 
pincer complexes where the acridine functionality is joined by either an AAC or an NHC ligand. The 
complexes were tested for their cytotoxicity towards three cancer cell lines, namely lung adenocarcinoma 
(A549), breast cancer (MCF-7) and leukaemia (HL60). The DNA binding abilities of the complexes 
towards dsDNA was also investigated using DNA FRET-melting assays. 
 
Results and discussion 
 
Synthesis and characterization 
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Following the work of Kilpin et al. who described the synthesis of cyclometalated (C^N)Au(III) 
complexes with (O^O), (N^O) and (N^N) ligands, we synthesized (N^O) and (N^N) chelate ligands 
bearing an acridine moiety. The reaction of 2-aminophenol with 2-(acridin-9-ylamino)-benzoic acid in the 
presence of N,N’-carbonyldiimidazole (CDI) did not proceed by coupling at the –COOH function as 
expected but instead gave the substituted phenol L1, with displacement of 2-aminobenzoic acid. The same 
reaction also occurred when o-phenylenediamine was used, affording L2 (Scheme 1). 
 
 
Scheme 1. Synthesis of the substituted acridine ligands L1 and L2. 
 
The reaction of the (C^N)gold(III) dichlorides 1 and 2 with 2-acetamidophenol in refluxing methanol in 
the presence of excess trimethylamine afforded high yields of the products 4 and 5, respectively (Scheme 
2), as previously reported.15 Complex 6 was synthesized by reacting 1 with 1,2-diacetamidobenzene and 
silver oxide in refluxing dichloromethane. The reaction of 2 with 1,2-diacetamidobenzene/Ag2O was also 
attempted but caused opening of the less rigid 6-membered ring. 
Complex 6 was poorly soluble in the deuterated NMR solvents and therefore signals in both the 
1H and particularly the 13C{1H} NMR were poorly resolved.  
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Scheme 2. Synthesis of the (C^N) cyclometalated gold(III) complexes 4-9. 
 
Complex 7 was obtained in high yield by reacting 1 with L1 in refluxing methanol in the presence of an 
excess of trimethylamine, followed by precipitation with water. The reaction of 2 and L1 under the same 
conditions was also successful and gave 8 in moderate yield. The corresponding (C^N)-(N^N) complex, 
complex 9 was obtained in good yield by the reaction of 1 with L2 under the same conditions. Once again, 
the reaction was also attempted with the 2-benzyl pyridine gold dichloride starting material but caused 
ring opening.  
At 25 °C solutions of 8in CD2Cl2 gave broadened NMR spectra indicative of hindered rotation. 
These sharpen on cooling to-10C and show well-resolved signals (see ESI, Figure S10) of the chemically 
inequivalent acridine protons H22-25. The characteristic AB system of two doublets for the methylene 
bridge at 4.43 ppm and 3.91 ppm was observed, indicating the diastereotopic nature of these protons. For 
the three acridine-based complexes 7-9, only one set of signals was observed for each proton, 
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demonstrating the formation of only one isomer in each case, as was also seen for the simpler (N^O) and 
(N^N) complexes 4-6. 
Slow diffusion of light petroleum into dichloromethane solutions of complexes 7 and 9 yielded 
crystals suitable for X-ray diffraction (Figure 3). In both compounds the square planar geometry of the 
gold(III) centres is slightly distorted due to the small bite angles of the cyclometalated ligand [respective 
C11-Au-N1 angles 81.1°(7) and 80.9° (9)]. In 7, the acridine-substituted nitrogen atom is in trans position 
to the nitrogen of the cyclometalated ligand, placing it on the same side as the tert-butyl substituent, while 
the O atom, as the weakest trans influence ligand, is trans to the stronger C-donor. The adopted 
conformation is therefore a reflection of the electronic preferences. The acridine moiety is twisted out of 
the coordination plane, with an Au1-N2-C22-C23torsion angle of 110 °, presumably to avoid steric 
hindrance with the tert-butyl substituent. As suggested by the NMR spectra, only one isomer of the 
complex was obtained. 
In complex 9, on the other hand, the second ligand is an N^N chelate, with both donor atoms 
having similar electronic properties. Therefore, in this case a conformation is adopted which places the 
acridine substituent distal from the t-butyl group, to minimise steric interactions. Here, too, the acridine 
moiety is twisted out of the coordination plane (torsion angle Au1-N3-C22-C23 67.3°).  
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Figure 3. Top: crystal structure of complex 7·CH2Cl2 (dichloromethane and hydrogen atoms omitted for 
clarity). Selected bond distances (Å) and angles (º). Au1-N1 2.028(3), Au1-C11 2.034(4), Au1-O1 
2.049(3), Au1-N2 1.990(3), C11-Au1-N1 81.1(1), C11-Au1-N2 103.8(1), N2-Au1-O1 82.5(1), O1-Au1-
N1 92.7(1), N1-Au1-N2 174.3(1), C11-Au1-O1 173.1(1), torsion Au1-N2-C22-C23 110.4(3). Bottom: 
Crystal structure of complex 9·CH2Cl2 (dichloromethane and hydrogen atoms omitted for clarity). 
Selected bond distances (Å) and angles (º). Au1-N1 2.063(7), Au1-C11 2.015(6), Au1-N2 1.956(8), Au1-
N3 2.081(6), N1-Au1-C11 80.9(3), C11-Au1-N2 95.2(3), N2-Au1-N3 80.3(3), N3-Au1-N1 103.9(3), 
Au1-N2-H100 119(6), N1-Au1-N2 175.4(3), C11-Au1-N3 173.0(3), torsion Au1-N3-C22-C23 67.3(9). 
 
The pyrazine-based pincer complex (C^Npz^C)AuCl (3) was synthesized as reported previously.27 
Conversion of 3 into the cationic xylylisocyanide complex [(C^Npz^C)Au(CNxyl)]+, followed by reaction 
with 9-aminoacridine afforded the functionalized acyclic amino carbene complexes 10 (Scheme 3). The 
yield was reduced due to the competitive hydrolysis of the highly electrophilic isocyanide adduct to the 
gold(III) formamide byproduct, as previously observed.17 
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Scheme 3. Synthesis of the acridine functionalized [(C^Npz^C)AuIII(AAC)]+ 10. 
Upon formation of 10, a broad NH singlet appears in the 1H spectrum at 10.34 ppm and the upfield H2 
shift to 9.13 ppm confirms that a reaction had occurred and suggests that the acyclic amino carbene has 
been formed. The signal for H8 at 9.96 ppm is also in good agreement with H8 signals observed for the 
AAC complexes synthesized previously.17 The IR spectrum of 10 showed a carbene vibration at 1586 cm-1 
and two NH stretches at 3388 cm-1 and 3270 cm-1.  
Complex 11 was synthesized in good yield by reacting an acridine functionalized imidazolium salt 
with silver oxide, followed by the addition of 3 and potassium hexafluorophosphate by adapting a known 
procedure (Scheme 4).28 The slight downfield shift in the signal for H2 and a larger downfield shift in H8 
from 7.88 to 7.21 ppm in the 1H NMR spectrum and the appearance of a signal at δC 154.9 ppm for the 
Au-bound NHC suggested carbene formation.  
 
Scheme 4. Synthesis of the acridine-functionalized [(C^Npz^C)AuIII(NHC)]+ 11. 
 
Biological Activity 
Although insoluble in aqueous cell culture medium, all the complexes and their ligand precursors 
were soluble enough in DMSO not to precipitate when diluted in 100 µM aqueous cell medium with 1% 
of DMSO. Complexes 1-11 and the acridine ligand precursors L1 and L2 were screened for their 
antiproliferative properties in vitro on a panel of human cancer cell lines, including lung adenocarcinoma 
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cells (A549), breast adenocarcinoma (MCF-7), and promyelocytic leukaemia (HL60). The IC50, (the 
concentration at which cell viability is reduced to 50%), was then determined using a colorimetric MTS 
assay after 72 h of incubation, with the cisplatin included for comparison (see Experimental part for 
details). The results are summarized in Table 1. 
 
Table 1: Cytotoxic effects of complexes 1-11 and ligands L1 and L2 in comparison to cisplatin towards 
different human cancer cell lines after 72 h of incubation. 
Complex 
IC50 ± SD (µM)a 
A549 MCF-7 HL60 
1 43.6 ± 4.1 10.8 ± 3.5 6.0 ± 0.5 
2 >100 38.7 ± 4.7 12.8 ± 0.3 
3b > 50 8.6 ± 1.1 3.7 ± 0.3 
4 12.7 ± 2.5 5.2 ± 1.0 2.9 ± 0.7 
5 10.8 ± 2.7 3.6 ± 1.4 2.7 ± 0.4 
6 22.7 ± 2.5 9.9 ± 2.1 2.5 ± 0.1 
7 16.6 ± 2.8 2.7 ± 0.9 1.4 ± 0.4 
8 19.9 ± 3.9 4.3 ± 0.4 1.5 ± 0.1 
9 17.2 ± 4.4 6.7 ± 1.6 6.3 ± 0.1 
10 15.0 ± 2.0 7.5 ± 0.6 20.7 ± 0.4 
11 7.6 ± 0.6 1.5 ± 0.1 1.1 ± 0.1 
L1 >100 >100 >100 
L2 23.9 ± 3.5 14.4 ± 0.9 16.9 ± 0.9 
Cisplatin 33.7 ± 3.7b 21.2 ± 3.9b 3.7 ± 0.3b 
a Mean ± the standard error of at least three independent experiments. b Values from ref. 18 
Complexes 4-11 showed greater or comparable activity to cisplatin under the conditions used in 
this assay and were overall more toxic than the gold dichloride precursors, complexes 1 and 2. The free 
ligands, L1 and L2, showed reduced toxicity particularly L1 which was inactive against all of the cell 
lines tested, with an IC50 value of >100 µM against all three. L2 also showed reduced toxicity in 
comparison to the gold complexes, which indicates that the goldIII centre contributes significantly to the 
cytotoxicity.  
Overall, the mono-cyclometalated (C^N)-(N^X) complexes, 4-9 showed greater activity than 
cisplatin against both the MCF-7 and the A549 human cancer cell lines and comparable activity against 
the HL60 cell line. Complexes 4-9 all showed similar activities against the MCF-7 cell lines, with 
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IC50values in the 2-10 µM range. Complexes 5, 7 and 8 showed particularly high toxicity with values 
between 2-4 µM. IC50 values for the A549 cell line were slightly higher, between 10-20 µM for all of the 
complexes. Here, the simpler structures, complexes 4 and 5 showed the greatest overall toxicity. 
Changing the (C^N) cyclometalated ligand from the rigid 5-ring (phenyl pyridine)to the flexible 
6-ring ligand (2-benzylpyridine) appeared to have no significant effect on the cytotoxicity of the 
complexes. For example, for the HL60 leukaemia cell line, complexes 4 and 5 have IC50values of 2.9 and 
2.7 µM, respectively. The same trend was found for complexes 7(1.4 µM) and 8(1.5 µM). This is different 
to results obtained by Kilpin et al., who found that complexes containing a six-membered cyclometalated 
ring displayed higher cytotoxicity than those with a five-membered cyclometalated ring.14 
For all three cell lines, the (N^O) chelates appeared to be slightly more cytotoxic than the 
corresponding N^N chelates, which is in contrast to the values obtained for the free acridine ligands, L1 
and L2. For example, for the A549 lung cancer cell line the (N^O) chelate, complex 4, has an IC50 of 12.7 
µM, while the corresponding (N^N) chelate 6 has an IC50 of 22.7 µM. The same pattern can be seen for 
the acridine-functionalized derivatives: 7, the (N^O) chelate, is more toxic than its (N^N) analogue 9 
against the all three cancer cell lines. Here the effect is most notable against the leukaemia HL60 cell line, 
(IC50 of 1.4 and 6.3 µM for 7 and 9, respectively). 
As a comparison of complexes 4 versus 7 and 5 versus 8 shows, adding an acridine functionality 
appeared not to increase the overall cytotoxicity of the mono-cyclometalated (C^N)-(N^X) complexes. 
This also holds for the (N^N) chelates 6 compared to 9, where the toxicity differences due to acridine are 
not significant.  
The [(C^Npz^C)Au(III)(AAC)]+ complex 10 showed a higher cytotoxicity than cisplatin against 
both the MCF-7 and the A549 cancer cell lines, although it showed reduced activity against the HL60 
cells (20.7 µM). These values are in good agreement with data on AAC complexes we reported earlier, 
particularly when considering the amino ester derivatives (e.g. GlyOEt – IC50 values of 6.4, 13.0 and 16.7 
µM for MCF-7, A549 and HL60 respectively).17 
The other (C^Npz^C) pincer complex, 11 with acridine functionality bound to the NHC ligand, 
showed the highest overall toxicity, with values in the low µM regions for all three cell lines. It was more 
than ten times more toxic than cisplatin against MCF-7 cells and 3-4 times more toxic against the A549 
and HL60 cell lines. Although our incubation time is longer (72 h instead of 24 h), it is interesting to note 
that 11 is active against A549 cells while the related AuI complex [Au(MeImAcr)2]+ is not.26b The higher 
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cytotoxicity of the [(C^Npz^C)Au(NHC)]+ complexes with respect to the [(C^Npz^C)Au(AAC)]+ 
complexes is in line with our previous results.17 
Cellular uptake into MCF-7 cells 
The cellular uptake and the accumulation of drugs inside the cell are both major factors that influence the 
cytotoxicity of prospective anticancer agents.29 Inductively coupled plasma-mass spectrometry, (ICP-MS) 
was used to quantify the amount of intracellular gold and thus measure the amount of compound taken up 
by the cell. In order to see whether the cytotoxicity of the complexes was influenced by their ability to be 
taken up by the cell, complexes 2, 6, 7 and 11 were chosen for uptake studies, since they show a range of 
antiproliferative activities against MCF-7 cells ranging from poor (IC50(2) of 38.7 µM) to high (IC50(11) 
of 1.5 µM) via intermediate activities (IC50(6) and IC50(7) of 9.9 µM2.7 µM respectively). Moreover, that 
selection of compounds includes a dichloro complex (2), a simple (N^X) chelate (6) and examples of 
acridine derivatives with (C^N) and (C^Npz^C) cyclometalated ligands (7 and 11 respectively). MCF-7 
cells were incubated for 6 h with 10 µM concentrations of each of the complexes in 1% DMSO. The 
results of three independent experiments are depicted in Figure 4. 
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Figure 4. Cellular uptake of complexes 2, 6, 7 and 11 and a DMSO control in MCF-7 cells after 6 h of 
treatment at 10 µM in 1% DMSO. Data represent the average ± standard deviation of three experiments. 
The significance of the results was analysed by t-test. **p value < 0.01. 
 
There was a clear correlation between cellular uptake and the in vitro cytotoxicity of the 
complexes, with the most cytotoxic complexes showing the highest levels of cell uptake (see Figure 6 and 
ESI, Figure S1). This suggests that the primary limitation for the poorly toxic complexes is their very low 
uptake into the cell. Such a correlation between cellular uptake and antiproliferative activity has also been 
observed for other gold complexes, including [(C^Npz^C)Au(NHC]+ complexes.18,30 The increase in cell 
uptake seems to follow the increasing lipophilicity of the complexes, which might suggest an 
internalization via passive diffusion, reminiscent of the process recently reported by Casini et al. for a 
phosphine analogue of 2.31 
 
DNA binding assays 
Acridine derivatives are known to interact with duplex DNA as well as higher order DNA 
structures and this can influence the cytotoxic properties of the compounds.22,23 DNA intercalators are of 
interest as probes in the study of ligand-DNA interactions and also as potential therapeutic agents.32 DNA 
intercalation is a reversible mode of DNA-ligand binding which consists of the direct insertion of planar 
aromatic moieties in between the base pairs of DNA, which causes unwinding to the double helix. There 
are several examples of gold(III) complexes acting as DNA intercalators, including both 
aminoquinoline,20a and terpyridine20b derivatives, which have been shown to bind to intracellular DNA by 
intercalation of the planar gold(III) coordination plane into the DNA base pairs. To determine whether or 
not the acridine-functionalized complexes interact with DNA in the present cases, a Fӧrster resonance 
energy transfer (FRET) DNA melting assay was used to measure the ability of 4–11, L1 and L2 to 
stabilize double stranded DNA. FRET is used as a tool for detecting spatial relationships between two 
fluorophores and involves measuring the changes in fluorescence as FRET donor and acceptor moieties 
are brought closer together or moved further apart as a result of DNA stabilization or denaturation. As a 
result of the large differences in fluorescence between folded and unfolded DNA structures it is possible 
to measure the interaction of a particular drug molecule with the DNA.33 Results are expressed as the 
changes in DNA melting temperature (ΔTm) when double stranded DNA (0.2 µM) is dosed with 50 µM 
concentrations of each drug (Figure 5). 
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Figure 5. Stabilization of double-stranded DNA (0.2 µM) by complexes 4-11 and L1/L2 at 50 µM 
concentrations measured by FRET DNA melting assay. Data represents the average and standard 
deviation of two separate experiments. 
 
Out of the eight complexes tested, only two showed the ability to stabilize double-stranded DNA. The 
acridine-free complexes 4, 5 and 6 actually appeared to slightly destabilize ds DNA. These results confirm 
the poor interaction between gold(III) and ds-DNA. None of the (4-tBu-phenylpyridine)-based complexes 
7 and 9 interacted with ds DNA, possibly due to the steric hindrance provided by the t-Bu substituted C^N 
ligand. The same phenomenon might be responsible for the lack of interaction of the AAC complex 10. 
Complex 8, the acridine functionalized 2-benzylpyridine derivative, showed high levels of DNA 
stabilization. This suggests that it is interacting with the ds DNA in some manner, potentially due to the 
hemi-lability of (C^N) ligand which could favour intercalation by decreasing steric hindrance. 
Interestingly, the [(C^Npz^C)Au(NHC)]+ complex 11 appeared to show significant interaction with ds-
DNA, while the closely related complex F (Figure 1) lacking the acridine moiety interacted with ds-DNA 
rather poorly.18 However, considering the poor DNA intercalation behaviour of the acridine ligands L1 
and L2 and the lack of interaction of most of the acridine-decorated complexes, it seems likely that the 
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interactions observed for 8 and 11 are due to mechanisms other than the simple intercalation of the 
acridine moiety. Overall, considering that 7 and 8 present very similar cytotoxicities but drastically 
different interactions with DNA, these data suggest that acridine-DNA interactions have little bearing on 
the cytotoxicity mechanism of this series of compounds. 
Reaction with Glutathione 
Reduction of gold(III) complexes by glutathione (GSH) to gold(I) and gold(0) products is a typical feature 
of this class of complexes.34 The stability of 11 and 7 towards reduction by GSH was therefore explored 
by 1H NMR spectroscopy. Each complex was mixed at room temperature with reduced GSH in a 1:1 
mixture of DMSO-d6 and D2O and monitored by over time. We had previously shown that a 
benzimidazole-based NHC complex of (C^Npz^C)Au(III) (Figure 1, structure F) is stable towards 
reduction by GSH.18 By contrast, the acridine substituted [(C^Npz^C)Au(NHC)]+ complex 11 appeared 
less stable, and over a 24 hour period the gradual formation of oxidized glutathione (GSSG) was observed, 
along with the disappearance of signals for reduced GSH (Figure 6). One can hypothesize that the higher 
steric hindrance around gold due to the acridine substituent on the NHC could facilitate the protolytic Au-
C bond cleavage leading to S-coordination of GSH and subsequent reduction of the gold(III) ion, 
following a reaction pathway similar to the one recently found for the reaction of adamantylthiol with 
(C^N^C)Au pincer compounds.35 The same pattern was seen for the acridine substituted (C^N)-(N^O) 
chelate complex, 7 (Figure S2). 
 
Figure 6. 1H NMR spectra of a 1:1 mixture of 11 with GSH at room temperature, in comparison with the 
starting materials, 11, GSH and GSSG (DMSO-d6/D2O 1:1). 
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Conclusion 
A new series of mono cyclometalated (C^N)(N^X)Au(III) complexes as well as two bis-cyclometalated 
(C^Npz^C) pincer complexes were synthesized, with and without acridine functionality.  These complexes 
were tested for their cytotoxicity towards three cancer cell lines. These studies identified complex 11, the 
NHC derivative, as the most promising candidate, with IC50 values in the low µM range for all three cell 
lines. However, the introduction of an acridine functionality did not appear to increase the cytotoxicity of 
the complexes. Cell uptake studies demonstrated a correlation between cellular uptake and the in vitro 
cytotoxicity of the complexes and indicated that cellular uptake is the primary limitation for non-toxic 
gold(III) complexes. DNA binding studies showed that two of the derivatives, complex 8 and the NHC 
derivative 11, demonstrate high levels of DNA stabilization suggestive of DNA intercalation. The lack of 
a correlation between the cytotoxicity data and the interaction with ds-DNA may suggest that the addition 
of the acridine moiety onto these scaffolds did not result in improved DNA targeting. Taken together, 
those data suggest that DNA is probably not the main target of that class of compounds and that more 
experiments are required to fully elucidate its involvement in the mechanism of action of these complexes. 
Moreover, both the pincer NHC complex [(C^Npz^C)Au(NHC)]+11 and the mono-cyclometalated 
(C^N)Au(N^O) derivative 7 were prone to reduction by glutathione at a time scale commensurate with 
incubation, which suggests that these compounds are reduced to gold(I) species in the cellular 
environment. Further work is required to investigate the localization and accumulation of those complexes 
within the cells and other possible modes of action of these complexes. 
 
Materials and methods 
 
General remarks. When required, manipulations were performed using standard Schlenk techniques under 
dry nitrogen or in a MBraun glove box. Nitrogen was purified by passing through columns of supported 
P2O5 with moisture indicator, and activated 4 Å molecular sieves. Anhydrous solvents were freshly 
distilled from appropriate drying agents. 1H and 13C[1H] spectra were recorded using a Bruker 
AvanceDPX-300 spectrometer. 1H NMR spectra (300.13 MHz) were referenced to the residual protons of 
the deuterated solvent used. 13C[1H] NMR spectra (75.47 MHz) were referenced internally to the D-
coupled 13C resonances of the NMR solvent. Elemental analyses were carried out at London Metropolitan 
University. Complexes 1, 2, 3 and 5 were synthesized following reported procedures.15,27,36,37 
Synthesis of complex 4 
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A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (1), (0.200 g, 0.418 mmol), 2-acetamidophenol 
(0.100 g, 0.661 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 mL) for 30 min. 
The reaction was then cooled and water (40 mL) was added causing an immediate orange precipitation. 
The flask was then placed in the freezer for two days. The orange solid was filtered and purified by 
dissolving in minimal dichloromethane (2 mL) and precipitating the product with an excess of light 
petroleum (bp. 40-60 °C) (20 mL). This was filtered and dried under vacuum (0.181 g, 0.325 mmol, 78%). 
Anal. Calcd. for C23H23AuN4O2.2H2O (592.45): C, 46.63; H, 4.59; N, 4.73. Found: C, 46.23; H 4.21; N 
4.76. 1H NMR (CD2Cl2, 300 MHz, 298 K): 8.97 (d, 3JH-H = 5.1 Hz, 1H, H2), 8.07 (t, 3JH-H = 8.1 Hz, 1H, 
H4), 7.83 (d, 3JH-H = 8.1 Hz, 1H, H5), 7.75 (d, 4JH-H = 1.5 Hz, 1H, H11), 7.51-7.40 (m, 2H, H3+8), 7.37 (dd, 
3JH-H = 8.3 Hz, 4JH-H = 1.5 Hz, 1H, H9), 7.22 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.3 Hz, 1H, H14/17), 6.84 (m, 1H, 
H15/16), 6.66 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.3 Hz, 1H, H14/17), 6.49 (m, 1H, H15/16), 2.32 (s, 3H, H20), 1.35 (s, 
9H, tBu). 13C[H] NMR (CD2Cl2, 75 MHz): 173.7 (s, C19), 164.2 (s, C12), 161.3 (s, C6/7), 155.5 (s, C6/7), 
147.0 (s, C2), 144.7 (s, C10), 144.3 (s, C13/18), 142.7 (s, C4), 139.4 (s, C13/18), 133.0 (s, C11), 125.4 (s, C3), 
124.8 (s, C8), 124.2 (s, C9), 123.8 (s, C14/17), 123.4 (s, C14/17), 120.2 (s, C5), 115.6 (s, C15/16), 115.3 (s, 
C15/16), 35.3 (s, C(CH3)3), 30.8 (s, C(CH3)3), 25.2 (s, C20). 
Synthesis of complex 6 
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (2) (0.200 g, 0.418 mmol), 1,2-
diacetamidobenzene (0.081 g, 0.421 mmol) and silverI oxide (200 mg, 0.863 mmol) was added to 
dichloromethane (30 mL) and refluxed for 24 h. The mixture was then cooled, filtered through celite and 
the filtrate was concentrated under vacuum. A large excess of diethyl ether (20 mL) was added to 
precipitate the product as a pale-yellow, fluffy, solid. This was filtered and dried under vacuum (0.224 g, 
0.375 mmol, 89%). Anal. Calcd. for C25H26AuN3O2 (597.47): C, 50.26; H, 4.39; N, 7.03. Found: C, 50.12; 
H 4.38; N 6.97. 1H NMR (CD2Cl2, 300 MHz, 298 K): 9.30 (s, 1H, H2), 8.02 (t, 3JH-H = 7.8 Hz, 1H, H4), 
7.79 (d, 3JH-H = 7.8 Hz, 1H, H5), 7.55 (d, 4JH-H = 1.4 Hz, 1H, H11), 7.48 (d, 3JH-H = 8.0 Hz, 1H, H8), 7.41-
7.28 (m, 3H, H9+3+14/17), 7.09 (m, 1H, H14/17), 6.99 (dt, 3JH-H = 7.3 Hz, 4JH-H = 1.4 Hz, 1H, H15/16), 6.91 (dt, 
3JH-H = 7.3 Hz, 4JH-H = 1.4 Hz, 1H, H15/16), 2.27 (s, 3H, H20/22), 2.15 (s, 3H, H20/22), 1.34 (s, 9H, tBu). 13C[H] 
NMR (CD2Cl2, 75 MHz): 174.1 (s, C19/21), 173.1 (s, C19/21), 164.6 (s, C12), 154.8 (s, C2), 153.3 (s, C6/7), 
145.5 (s, C10), 142.2 (s, C4), 140.5 (s, C13/18), 130.8 (s, C11), 125.5 (s, C3/9), 124.6 (s, C15/16), 124.2 (s, C8), 
124.0 (s, C14/17), 123.0 (s, C3/9), 122.7 (s, C15/16), 119.7 (s, C5), 35.3 (s, C(CH3)3), 30.8 (s, C(CH3)3).  
Synthesis of complex 7 
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (1), (0.235 g, 0.491 mmol), ligand L1 (0.300 g, 
1.048 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 mL) for 30 min. The 
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reaction was then cooled and water (40 mL) was added causing an immediate dark brown precipitation. 
The flask was placed in the freezer for two days. The brown solid was filtered off and purified by 
dissolving in dichloromethane (2 mL), followed by precipitation an excess of light petroleum (bp. 40-60 
°C) (20 mL). This product was filtered off and dried under vacuum (0.273 g, 0.394 mmol, 80%). Anal. 
Calcd. for C34H28AuN3O (691.19): C, 59.05; H, 4.08; N, 6.08. Found: C, 58.84; H 4.13; N 6.02. 1H NMR 
(CD2Cl2, 300 MHz, 298 K): 9.61 (dd, 3JH-H = 5.9 Hz, 4JH-H = 1.0 Hz, 1H, H2), 8.49 (dd, 3JH-H = 8.7 Hz, 4JH-
H = 0.7 Hz, 2H, H21/24), 8.30 (d, 3JH-H = 8.7 Hz, 2H, H21/24), 8.08 (dt, 3JH-H = 8.1 Hz, 4JH-H = 1.0 Hz, 1H, 
H4), 7.82 (d, 3JH-H = 8.1 Hz, 1H, H5), 7.75 (m, 2H, H22/23), 7.54 (m, 1H, H3), 7.48-7.36 (m, 3H, H8+22/23), 
7.01 (dd, 3JH-H = 8.2 Hz, 4JH-H = 1.7 Hz, 1H, H9), 6.85 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.2 Hz, 1H, H14/17), 6.48 
(dt, 3JH-H = 7.7 Hz, 4JH-H = 1.2 Hz, 1H, H15/16), 6.12 (dt, 3JH-H = 7.7 Hz, 4JH-H = 1.2 Hz, 1H, H15/16), 5.39 (dd, 
3JH-H = 7.7 Hz, 4JH-H = 1.2 Hz, 1H, H14/17), 5.23 (d, 4JH-H = 1.7 Hz, 1H, H11), 0.35 (s, 9H, tBu). 13C[H] NMR 
(CD2Cl2, 75 MHz): 163.3 (s, C2), 156.1 (s, C12), 155.2 (s, C6/7), 153.3 (s, C6/7), 151.0 (s, C19), 150.9 (s, 
C20), 147.5 (s, C10), 142.5 (s, C13/18), 141.9 (s, C4), 140.2 (s, C13/18), 130.3 (s, C21), 130.2 (s, C22), 127.4 (s, 
C9), 126.2 (s, C23), 125.4 (s, C8), 124.5 (s, C25), 124.3 (s, C24), 124.0 (s, C11), 123.5 (s, C3), 120.2 (s, C5), 
118.4 (s, C15/16), 117.0 (s, C15/16), 115.1 (s, C14/17), 113.7 (s, C14/17), 34.4 (s, C(CH3)3), 29.9 (s, C(CH3)3). 
Synthesis of complex 8 
A mixture of 2-benzylpyridine gold dichloride, (2), (0.200 g, 0.459 mmol), ligand L1 (0.178 g, 0.622 
mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 mL) for 30 min. The reaction 
was then cooled and water (40 mL) was added causing an immediate dark brown precipitation. The flask 
was then placed in the freezer for two days. The brown solid was then filtered and purified by dissolving 
in minimal dichloromethane and acetone (3 mL). the product was precipitated with an excess of light 
petroleum (bp. 40-60 °C) (20 mL), filtered off and dried under vacuum (0.201 g, 0.309 mmol, 67%). 
Anal.Calcd.for C31H22AuN3O.5H2O (739.58): C, 50.35; H, 4.36; N, 5.68. Found: C, 50.63; H 3.36; N 7.45. 
1H NMR (CD2Cl2, 300 MHz, 263 K): 9.23 (d, 3JH-H = 5.6 Hz, 1H, H2), 8.51 (d, 3JH-H = 8.6 Hz, 1H, H22/25), 
8.46 (d, 3JH-H = 8.6 Hz, 1H, H22/25), 8.21 (d, 3JH-H = 8.6 Hz, 1H, H22/25), 8.03 (dt, 3JH-H = 7.7 Hz, 4JH-H = 1.4 
Hz, 1H, H4), 7.95 (d, 3JH-H = 8.6 Hz, 1H, H22/25), 7.80 (m, 1H, H23/24), 7.67 (d, 3JH-H = 7.7 Hz, 1H, H5), 
7.62-7.46 (m, 3H, H3+23/24), 7.25 (t, 3JH-H = 8.6 Hz, 1H, H23/24), 6.78-6.71 (m, 2H, H15/18+9/12), 6.55 (t, 3JH-H 
= 7.4 Hz, 1H, H16/17), 6.47 (t, 3JH-H = 7.4 Hz, 1H, H10/11), 6.16 (t, 3JH-H = 7.4 Hz, 1H, H16/17), 5.99-5.84 (m, 
2H, H9/12+10/11), 5.69 (dd, 3JH-H = 7.4 Hz, 4JH-H = 1.0 Hz, 1H, H15/18), 4.43 (d, 2JH-H = 15.3 Hz, 1H, H7/7’), 
3.91 (d, 2JH-H = 15.3 Hz, 1H, H7/7’). 13C[H] NMR (CD2Cl2, 75 MHz): 157.2 (s, C13), 157.1 (s, C6/8), 151.7 
(s, C6/8), 151.5 (s, C14/19), 150.7 (s, C2), 141.7 (s, C4), 138.5 (s, C14/19), 132.3 (s, C20/21/26), 130.2 (s, C22/25), 
130.1 (s, C9/12), 129.8 (s, C22/25), 129.5 (s, C23/24), 126.4 (s, C9/12), 126.4 (s, C10/11), 126.4 (s, C10/11), 126.1 
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(s, C5), 125.6 (s, C23/24), 124.7 (s, C3), 118.3 (s, C16/17), 116.7 (s, C16/17), 115.4 (s, C15/18), 113.4 (s, C15/18), 
47.8 (s, C7/7’).  
Synthesis of complex 9 
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (1), (0.200 g, 0.418 mmol), ligand L2 (0.177 g, 
0.620 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 mL) for 30 min. The 
reaction was then cooled and water (40 mL) was added causing an immediate light brown precipitation. 
The flask was then placed in the freezer for two days. The brown solid was then filtered and purified by 
dissolving in minimal dichloromethane (2 mL). The product was precipitated with an excess of light 
petroleum (bp. 40-60 °C) (20 mL), filtered off and dried under vacuum (0.214 g, 0.310 mmol, 74%). Anal. 
Calcd. for C34H29AuN4.3H2O (744.65): C, 54.84; H, 4.74; N, 7.52. Found: C, 54.25; H; 4.20 N; 7.41. 1H 
NMR (CD2Cl2, 300 MHz, 298 K): 8.40 (dd, 3JH-H = 8.7 Hz, 4JH-H = 0.7 Hz, 2H, H21/24), 8.24 (d, 3JH-H = 8.7 
Hz, 2H, H21/24), 7.78-7.68 (m, 4H, H22/23+2+4/5), 7.64-7.55 (m, 2H, H3+4/5), 7.41 (dd, 3JH-H = 8.2 Hz, 4JH-H = 
1.7 Hz, 1H, H9), 7.35 (m, 2H, H22/23), 6.97 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.1 Hz, 1H, H14/17), 6.44 (t, 3JH-H = 
7.7 Hz, 1H, H15/16), 6.36-6.18 (m, 3H, H8+11+15/16), 5.62 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.1 Hz, 1H, H14/17), 1.46 
(s, 9H, tBu). 13C[H] NMR (CD2Cl2, 75 MHz): 164.6 (s, C2), 155.3 (s, C12), 154.5 (s, C6/7), 150.5 (s, C6/7), 
149.6 (s, C19), 148.0 (s, C20), 145.6 (s, C10), 145.0 (s, C13/18), 140.4 (s, C4), 139.7 (s, C13/18), 130.2 (s, 
C21/24), 130.0 (s, C21/24), 126.5 (s, C25), 126.0 (s, C9), 125.5 (s, C22/23), 124.9 (s, C8), 124.8 (s, C22/23), 124.6 
(s, C11), 122.3 (s, C3), 120.1 (s, C5), 118.2 (s, C15/16), 116.3 (s, C15/16), 113.3 (s, C14/17), 112.6 (s, C14/17), 
35.6 (s, C(CH3)3), 31.0 (s, C(CH3)3). 
Synthesis of complex 10 
A mixture of (C^Npz^C)AuCl, (3), (0.060 g, 0.104 mmol), 2,6-dimethylphenyl isocyanide (0.016 g, 0.125 
mmol), AgSbF6 (0.043 g, 0.125 mmol) and a few pellets of 4A molecular sieves were combined in a 
flame-dried Schlenk flask under a nitrogen atmosphere with dry dichloromethane (15 mL). The mixture 
was left to stir at room temperature for 4 h. A white precipitate of AgCl was removed by filtration through 
celite, and the filtrate collected under an N2 atmosphere. The solvent was evaporated to a minimum and 
the product precipitated with an excess of light petroleum (bp. 40-60 °C). The supernatant was removed 
and the residue dried under vacuum to yield a yellow solid. 9-amino acridine (0.028 g, 0.146 mmol) was 
added to a flame-dried Schlenk flask. The solution was sonicated for 30 min and transferred to a separate 
flame-dried Schlenk flask containing the [(C^Npz^C)Au(2,6-dimethylphenyl isocyanide)]SbF6. The 
reaction was then stirred for 16 h at room temperature and the precipitate removed from solution via 
filtration through a celite plug. Next, the solvent was removed under vacuum and the solid residue re-
dissolved in dichloromethane (2 mL). The product was precipitated using a 2:1 mixture of light petroleum 
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(bp. 40-60 °C) / diethyl ether (5 mL). After removal of the solvent, the residue was dried under vacuum to 
yield a dark yellow solid. Proton NMR showed a mixture of the desired product and the formamide 
hydrolysis product. The solid was washed twice with dry dichloromethane (40 mL) followed by light 
petroleum (10 mL) and dried under vacuum (0.053 g, 0.048 mmol, 46%). Anal. Calcd. for 
C46H45AuF6N5Sb (1100.62): C, 50.20; H, 4.12; N, 6.36. Found: C, 49.97; H 4.03; N 6.35. 1H NMR 
((CD3)2SO, 300 MHz, 298 K): 10.34 (s, 1H, NH), 9.13 (s, 2H, H2), 8.26 (d, 3JH-H = 8.2 Hz, 2H, H20/23), 
7.96 (d, 4JH-H = 1.5 Hz, 2H, H8), 7.85 (d, 3JH-H = 8.4 Hz, 2H, H5), 7.74-7.57 (m, 4H, H20/23+21/22), 7.30 (dd, 
3JH-H = 8.4 Hz, 4JH-H = 1.5 Hz,2H, H6), 7.25-7.14 (m, 3H, H14+15), 6.96 (t, 2H, 3JH-H 7.5 Hz, 2H, H21/22), 
2.56 (s, 6H, H16), 1.20 (s, 18H, tBu). 13C[H] NMR (CD3CN, 75 MHz): 167.6 (s, C9), 156.0 (s, C4), 155.6 
(s, C3), 144.7 (s, C7), 139.9 (s, C2), 139.6 (s, C13), 135.1 (s, C8), 134.0 (s, C20/23), 128.6 (s, C15), 127.7 (s, 
C14), 127.6 (s, C20/23), 127.6 (s, C12), 127.0 (s, C5), 124.5 (s, C6), 123.6 (s, C21/22), 123.5 (s, C21/22), 117.8 (s, 
C18), 117.8 (s, C19), 117.8 (s, C24), 35.7 (s, C(CH3)3), 31.4 (s, C(CH3)3), 19.3 (s, C16). νmax (neat)/cm-1: 3388 
(NH), 3270 (NH) 2957 (tBu), 2867 (Ar), 1586 (carbene). 
Synthesis of complex 11 
[(MeImAcr)H]Cl (0.070 g, 0.232 mmol) and silver oxide (0.043 g, 0.186 mmol) and acetonitrile (15 mL) 
were combined in a Schlenk and stirred for 56 h. (C^Npz^C)AuCl, (3), (0.133 g, 0.232 mmol) and KPF6 
(0.128 g, 0.695 mmol) were then added to the flask and the reaction was stirred for a further 16 h before 
being filtered through a celite plug. The filtrate was concentrated under vacuum and the product was 
precipitated using a 2:1 mixture of light petroleum (bp. 40-60 °C) / diethyl ether (5 mL), and after 
removing the solvent, dried under vacuum to yield a dark yellow solid (0.170 g, 0.180 mmol, 78%). Anal. 
Calcd. for C41H39AuF6N5P.5MeCN (1148.99): C, 53.31; H, 4.74; N, 12.19. Found: C, 52.92; H, 5.10; N, 
11.80.1H NMR (CD3CN, 300 MHz, 298 K): 8.68 (s, 2H, H2), 8.12-8.02 (m, 3H, H11+19), 7.96 (d, 1H, 3JH-H 
= 1.9 Hz, H12), 7.88-7.77 (m, 4H, H16+18), 7.55 (d, 2H, 3JH-H = 8.3 Hz, H5), 7.45 (t, 2H, 3JH-H = 7.8 Hz, H17), 
7.33 (dd, 2H, 3JH-H = 8.3 Hz, 4JH-H = 1.7 Hz, H6), 7.21 (d, 2H, 4JH-H = 1.7 Hz, H8), 4.15 (s, 3H, H13), 1.30 
(s, 18H, tBu). 13C[H] NMR (CD3CN, 75 MHz): 166.1 (s, C9), 156.8 (s, C4), 156.3 (s, C3), 154.9 (s, C10), 
146.6 (s, C20), 144.6 (s, C7), 140.5 (s, C14), 139.3 (s, C2), 133.3 (s, C18), 133.0 (s, C8), 128.9 (s, C17), 127.0 
(s, C12), 126.9 (s, C19), 126.7 (s, C5), 126.3 (s, C11), 125.2 (s, C6), 123.5 (s, C16), 122.2 (s, C15), 39.1 (s, 
C13), 35.1 (s, C(CH3)3), 30.3 (s, C(CH3)3). 
Synthesis of L1 
2-(Acridin-9-ylamino)-benzoic acid (0.600 g, 2.100 mmol) and N,N’-carbonyldiimidazol(CDI) (0.341 g, 
2.103 mmol) were placed in a flame dried flask, fitted with a condenser and stirred in dry tetrahydrofuran 
(20 mL) under a nitrogen atmosphere, for 15 min. 2-amino phenol (0.301 g, 2.758 mmol) was then added 
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and the reaction was stirred for a further 15 min before being heated to reflux overnight. After cooling to 
room temperature, the orange solid was filtered and washed twice with light petroleum (bp. 40-60 °C) 
before being dried under vacuum (0.551 g, 1.925 mmol, 92%). 1H NMR ((CD2)SO, 300 MHz, 298 K): 
10.18 (s, 1H, H8), 8.26 (d, 3JH-H = 8.8 Hz, 1H, H3/6), 8.18 (d, 3JH-H = 7.9 Hz, 1H, H3/6), 8.08-7.88 (m, 5H, 
H4/5+11+14) 8.28-7.50 (m, 4H, H12+13), 7.03 (t, 3JH-H = 7.9 Hz, 1H, H4/5). 13C[H] NMR ((CD2)SO, 75 MHz): 
156.8 (s, C2/7/9), 152.9 (s, C2/7/9), 140.5 (s, C2/7/9), 136.1 (s, C11/14), 131.9 (s, C4/5), 130.5 (s, C10/15), 128.1 (s, 
C3/6), 128.0 (s, C12/13), 125.9 (s, C3/6), 124.6 (s, C12/13), 121.0 (s, C10/15), 119.9 (s, C11/14), 117.8 (s, C4/5), 
114.1 (s, Cq). 
Synthesis of L2 
4-(Acridin-9-ylamino)-benzoic acid (1.500 g, 4.772 mmol) and N,N’-carbonyldiimidazol (CDI) (0.774 g, 
4.773 mmol) were placed in a flame dried flask, fitted with a condenser, and stirred in dry tetrahydrofuran 
(50 mL) under a nitrogen atmosphere for 15 min. O-phenylenediamine (0.675 g, 6.242 mmol) was then 
added and the reaction was stirred for a further 15 min before being heated to reflux overnight. After 
cooling to room temperature, the orange solid was filtered and washed twice with light petroleum (bp. 40-
60 °C) before being dried under vacuum (1.102 g, 3.862 mmol, 81%). 1H NMR ((CD2)SO, 300 MHz, 298 
K): 8.24 (d, 3JH-H = 8.1 Hz, 2H, H11/14), 8.02 (d, 3JH-H = 8.1 Hz, 2H, H11/14), 7.90 (t, 3JH-H = 8.1 Hz, 2H, 
H12/13), 7.33 (t, 3JH-H = 8.1 Hz, 2H, H12/13), 7.18 (t, 3JH-H = 7.7 Hz, 1H, H4/5), 7.05 (d, 3JH-H = 7.7 Hz, 1H, 
H3/6), 6.89 (d, 3JH-H = 7.6 Hz, 1H, H3/6), 6.60 (t, 3JH-H = 7.6 Hz, 1H, H4/5). 13C[H] NMR ((CD2)SO, 75 
MHz): 156.5 (s, C2/7/9),145.1 (s, C2/7/9), 140.3 (s, C2/7/9), 135.3 (s, C12/13), 129.9 (s, C4/5), 127.2 (s, C3/6), 
126.2 (s, C11/14), 125.0 (s, C10/15), 123.7 (s, C12/13), 119.2 (s, C11/14), 116.9 (s, C4/5), 116.3 (s, C3/6),113.6 (s, 
C10/15). 
X-ray crystallography 
Description of the crystals: The crystals were mounted on a MiTeGen MicroMesh and fixed in a cold 
nitrogen stream. Diffraction intensities were recorded at 298, 173 or 140 K on a Rigaku HG Saturn724+ 
(2×2 bin mode) diffractometer or an Oxford Diffraction Xcalibur-3 instrument, both equipped with Mo-
Kα radiation. Data collection, refinement and reduction were performed using the CrystalClear-SM Expert 
3.1 b27 or CrysAlisPro software and the absorption correction was applied at this stage.38All structures 
were solved using SHELXS/T and refined by full-matrix least-squares methods on F2 with SHELXL.39 
Non-hydrogen atoms were refined with anisotropic thermal parameters. Hydrogen atoms were included in 
idealised positions. No missed symmetry was reported by PLATON.40 Computer programs used in this 
analysis were run through WinGX.41 Scattering factors for neutral atoms were taken from reference.42 
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Antiproliferation assay 
The human A549 and HL60 cancer cell lines (from ECACC) were cultured in RPMI 1640 medium with 
10% fetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg mL−1 streptomycin 
(Invitrogen). The cells were maintained under a humidified atmosphere at 37 °C and 5% CO2. The human 
MCF-7 cancer cell line (from ECACC) was cultured in DMEM medium with 10% fetal calf serum, 2 mM 
L-glutamine, 100 U mL−1 penicillin and 100 µg mL−1 streptomycin (Invitrogen). The cells were 
maintained under a humidified atmosphere at 37 °C and 5% CO2. Inhibition of cancer cell proliferation 
was measured by the 3-(4,5-dimethylthiazol-2-yl)5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) 
and following the manufacturer’s instructions. Briefly, the cells (3 × 104 per 100 µL for HL60, 8 × 103 per 
100 µL for A549 and MCF-7) were seeded in 96-well plates and left untreated or treated with 1 µL of 
DMSO (vehicle control) or 1 µL of complexes diluted in DMSO at diﬀerent concentrations, in triplicate 
for 72 h at 37 °C with 5% CO2. Following this, MTS assay reagent was added for 4 h and absorbance 
measured at 490 nm using a Polarstar Optima microplate reader (BMG Labtech). IC50 values were 
calculated using GraphPad Prism Version 5.0 software. 
 
Uptake study 
 
MCF-7 cells were grown in 75 cm2 flasks up to 70% of confluence in 10 mL of culture medium. 
Compounds 2, 5, 6 and 11 were added to the flasks (100 µL of 1 mM solution in DMSO) and incubated 
for 6 h at 37 °C with 5% CO2. Negative controls were used by incubating cells with DMSO alone under 
the same conditions. After removal of the medium and washing of the cells with PBS pH 7.4, the cells 
were detached using a trypsin solution. After quenching of trypsin with fresh medium, centrifugation and 
removal of the supernatant, the cell pellet was resuspended into 1 mL of PBS pH 7.4 and split into twice 
500 µL for metal and protein quantification. The number of cells (expressed per million cells) of each 
sample was determined by measuring the protein content of the treated samples using a BCA assay 
(ThermoFischer Scientific) corrected by the amount of protein/106 cells determined for each cell type by 
measuring the protein content of an untreated sample and dividing by the corresponding number of cells 
measured with a hematocytometer following a reported procedure. Microwave digestion was used to 
solvate the samples to liquid form. Nitric acid and hydrogen peroxide were used in a Milestone Ethos 1 
microwave system using SK-10 10 place carousel. The digest was ramped to 200 °C in 15 minutes holding 
at 200 °C for 15 min. The sample was weighed into a microwave vessel before digestion, and decanted and 
rinsed into a pre- weighed PFA bottle after digestion. ICP-MS samples were spiked with rhodium internal 
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standard and run on a Thermo X series 1 ICP-MS. The isotopes selected were 63Cu, 65Cu, 107Ag, 109Ag and 
197Au. Certified standards and independent reference were used for accuracy. Acid blanks were run 
through the system and subtracted from sample measurements before corrections for dilution. 
 
FRET assay. 
 
The initial FRET melting screen was performed using a fluorescence resonance energy transfer (FRET) 
DNA melting based assay. The sequence used was DSFRET FAM-d(TAT-AGC-TAT-A-HEG(18)-TAT-
AGC-TAT-A)-TAMRA-3′). The labelled oligonucleotide (donor fluorophore FAM is 6-
carboxyfluorescein; acceptor fluorophore TAMRA is 6-carboxytetramethyl-rhodamine) were prepared as 
a 220 nM solution in 10 mM sodium cacodylate buffer at the indicated pH with 100 mM sodium chloride 
and then thermally annealed. Strip-tubes (QIAgen) were prepared by aliquoting 20 μL of the annealed 
DNA, followed by 0.5 μL of the compound solutions. Control samples for each run were prepared with 
the same quantity of DMSO with the DNA in buffer. Fluorescence melting curves were determined in a 
QIAgen Rotor-Gene Q-series PCR machine, using a total reaction volume of 20.5 μL. Measurements were 
made with excitation at 470 nm and detection at 510 nm. Final analysis of the data was carried out using 
QIAgen Rotor-Gene Q-series software and Origin or Excel.  
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